GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (NAS:RPRX) » Definitions » 3-Year Dividend Growth Rate

Royalty Pharma (Royalty Pharma) 3-Year Dividend Growth Rate

: 38.70% (As of Dec. 2023)
View and export this data going back to 2020. Start your Free Trial

Royalty Pharma's Dividends per Share for the three months ended in Dec. 2023 was $0.20.

The historical rank and industry rank for Royalty Pharma's 3-Year Dividend Growth Rate or its related term are showing as below:

RPRX' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 38.7   Med: 38.7   Max: 38.7
Current: 38.7

During the past 7 years, the highest 3-Year average Dividends Per Share Growth Rate of Royalty Pharma was 38.70% per year. The lowest was 38.70% per year. And the median was 38.70% per year.

RPRX's 3-Year Dividend Growth Rate is ranked better than
80% of 65 companies
in the Biotechnology industry
Industry Median: 14.5 vs RPRX: 38.70

During the past 12 months, Royalty Pharma's average Dividends Per Share Growth Rate was 5.30% per year. During the past 3 years, the average Dividends Per Share Growth Rate was 38.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Royalty Pharma's Dividend Payout Ratio for the three months ended in Dec. 2023 was 0.24. As of today, Royalty Pharma's Dividend Yield % is 2.91%.

Good Sign:

Royalty Pharma PLC stock dividend yield is close to 5-year high.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison

For the Biotechnology subindustry, Royalty Pharma's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Royalty Pharma 3-Year Dividend Growth Rate Distribution

For the Biotechnology industry and Healthcare sector, Royalty Pharma's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Royalty Pharma's 3-Year Dividend Growth Rate falls into.



Royalty Pharma 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.


Royalty Pharma  (NAS:RPRX) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Royalty Pharma's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Dec. 2023 )/ EPS without NRI (Q: Dec. 2023 )
=0.2/ 0.826
=0.24

During the past 7 years, the highest Dividend Payout Ratio of Royalty Pharma was 0.55. The lowest was 0.33. And the median was 0.41.

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Royalty Pharma Recent Full-Year* Dividend History

Amount Ex-date Record Date Pay Date Type Frequency Forex Rate
USD 0.2102024-02-152024-02-162024-03-15Cash DividendquarterlyUSD:USD 1.000000
USD 0.2002023-11-162023-11-172023-12-15Cash DividendquarterlyUSD:USD 1.000000
USD 0.2002023-08-172023-08-182023-09-15Cash DividendquarterlyUSD:USD 1.000000
USD 0.2002023-05-182023-05-192023-06-15Cash DividendquarterlyUSD:USD 1.000000

* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.

Royalty Pharma's Dividend Yield (%) for Today is calculated as

Dividend Yield %=Most Recent Full Year Dividend/Current Share Price
=0.81/28.035
=2.89 %

Current Share Price is $28.035.
Royalty Pharma's Dividends per Share for the trailing twelve months (TTM) ended in Today is $0.81.

During the past 7 years, the highest Dividend Yield of Royalty Pharma was 3.01%. The lowest was 0.31%. And the median was 1.74%.

Good Sign:

Royalty Pharma PLC stock dividend yield is close to 5-year high.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Royalty Pharma 3-Year Dividend Growth Rate Related Terms>


Royalty Pharma (Royalty Pharma) Business Description

Traded in Other Exchanges
Address
110 East 59th Street, FL 33, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Executives
Rory B Riggs director 65 RAILROAD AVE, RIDGEFIELD NJ 07657
Avara Management Ltd 10 percent owner C/O GISEV FAMILY OFFICE SA, CONTRADA DI SASSELLO 2, LUGANO V8 6900
Terrance P. Coyne officer: EVP & CFO C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Pablo G. Legorreta director, officer: CEO, Chairman of the Board 110 E 59TH STREET, SUITE 3300, NEW YORK NY 10022
George W. Lloyd officer: EVP, Investments & GC C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Marshall Urist officer: EVP, Research & Investments C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Mario Germano Giuliani director, 10 percent owner C/O GISEV FAMILY OFFICE SA, CONTRADA DI SASSELLO 2, LUGANO V8 6900
James F. Reddoch officer: EVP, Research & Investments C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Nogra Group Sicaf Sif Gg Strategic 10 percent owner C/O NOGRA GROUP SICAF-SIF S.A., 18 AVENUE DE LA PORTE NEUVE, LUXEMBOURG N4 L-2227
Nogra Group Sicaf - Sif S.a. 10 percent owner 18 AVENUE DE LA PORTE NEUVE, LUXEMBOURG N4 L-2227
Catherine M. Engelbert director 110 NORTH CARPENTER STREET, CHICAGO IL 60607
Errol B Desouza director 215 COLLEGE ROAD, PARAMUS NJ 07652
Henry A Fernandez director MSCI INC., 88 PINE STREET, NEW YORK NY 10005
Gregory Norden director 16640 CHESTERFIELD GROVE DRIVE, SUITE 200, CHESTERFIELD MO 63005
Ted W Love director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080